Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H15N.ClH |
Molecular Weight | 245.747 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@]12C[C@]1(CNC2)C3=CC4=C(C=CC=C4)C=C3
InChI
InChIKey=ACVMJAJGCQUPKX-LIOBNPLQSA-N
InChI=1S/C15H15N.ClH/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15;/h1-7,14,16H,8-10H2;1H/t14-,15+;/m1./s1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C15H15N |
Molecular Weight | 209.2863 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Centanafadine is an oral triple reuptake inhibitor that has been developed by DOV Pharmaceutical as a treatment for attention-deficit hyperactivity disorder (ADHD). Centanafadine works by modulating the activity of norepinephrine, dopamine, and serotonin, three neurotransmitters known to be relevant in patients with ADHD. In the human abuse liability study, immediate-release centanafadine demonstrated a reduced abuse potential compared with the schedule II stimulants d-amphetamine and lisdexamfetamine. Treatment with high doses of immediate-release centanafadine resulted in a markedly different profile than that of the comparators, with most subjects experiencing the acute onset of adverse effects, including nausea, vomiting, and dysphoria. Almost 2 hours after the administration of centanafadine, the test subjects reported “liking” at about two-thirds of the magnitude of amphetamines, a finding that may have indicated dopamine activity. However, unlike amphetamines, which provided an immediate positive experience, the subjects receiving centanafadine experienced negative effects before reaching that point.
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:27:08 GMT 2023
by
admin
on
Sat Dec 16 08:27:08 GMT 2023
|
Record UNII |
265DN9X85W
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
265DN9X85W
Created by
admin on Sat Dec 16 08:27:08 GMT 2023 , Edited by admin on Sat Dec 16 08:27:08 GMT 2023
|
PRIMARY | |||
|
AB-16
Created by
admin on Sat Dec 16 08:27:08 GMT 2023 , Edited by admin on Sat Dec 16 08:27:08 GMT 2023
|
PRIMARY | |||
|
CHEMBL3301621
Created by
admin on Sat Dec 16 08:27:08 GMT 2023 , Edited by admin on Sat Dec 16 08:27:08 GMT 2023
|
PRIMARY | |||
|
68943792
Created by
admin on Sat Dec 16 08:27:08 GMT 2023 , Edited by admin on Sat Dec 16 08:27:08 GMT 2023
|
PRIMARY | |||
|
300000024927
Created by
admin on Sat Dec 16 08:27:08 GMT 2023 , Edited by admin on Sat Dec 16 08:27:08 GMT 2023
|
PRIMARY | |||
|
C166543
Created by
admin on Sat Dec 16 08:27:08 GMT 2023 , Edited by admin on Sat Dec 16 08:27:08 GMT 2023
|
PRIMARY | |||
|
923981-14-0
Created by
admin on Sat Dec 16 08:27:08 GMT 2023 , Edited by admin on Sat Dec 16 08:27:08 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |